
Hedia in partnership with Glooko
Hedia’s bolus calculator is available directly within the Glooko® Mobile App.

Innovative solution for improved diabetes management
Hedia develops a Digital Therapeutic (DTx) solution that covers self-management of diabetes.
Our goal is simple: to improve the quality of life for people with diabetes.
Hedia Diabetes Assistant
A class IIb medical device designed to support the management of insulin-requiring diabetes.
Developed in close collaboration with patients, nurses, and other key stakeholders, our goal is to help patients achieve better health outcomes, including greater stability of blood glucose levels, by providing tools to manage diabetes more effectively. Hedia Diabetes Assistant is currently available in multiple European countries.
You get access to Hedia Diabetes Assistant through your healthcare professional.

See why our users love Hedia Diabetes Assistant






Discover the clinical impact of Hedia Diabetes Assistant
We conduct research and scientific studies to ensure Hedia Diabetes Assistant delivers real results for our users. Our latest studies showed HDA:
- Lowers risk of hypoglycemia in new users after 12 weeks
- Improves eA1c in users with suboptimal control

Our clinical development plan
We’re committed to collecting high-quality clinical data for Hedia Diabetes Assistant.
Our CE-marked product is available on the market.
The next generation of Hedia Diabetes Assistant is under development and will soon enter clinical testing.

Featured in
Selskabet har på det seneste rejst 32,5 mio. kr. og går nu atter på kapitaljagt. Målet er sorte tal på bundlinjen i 2027 og på sigt et salg til en industriel spiller inden for diabetesfeltet.
Les thérapies numériques (DTx) contribuent à la prise en charge du diabète et offrent de nouvelles perspectives pour améliorer l’observance des patients.
New integration delivers personalised insulin dosing advice, improving care for people with diabetes and enhancing healthcare provider insights.
Hedia has raised €3 million in a seed extension round, supported by existing shareholders and Business Angels.
After eight years of product development, Hedia is getting ready for the commercialization phase. The Copenhagen-based diabetes company Hedia has raised DKK 22.5m (USD 3.3m) in a recently completed investor round.
Glooko and Hedia launched an interoperable solution to support advanced bolus insulin dosing. It combines connected care, remote monitoring, and digital therapeutics to help people with type 1 and type 2 diabetes.
Hedia annonce le lancement d’une étude clinique en France visant à évaluer l’impact de sa thérapie numérique DTX Hedia Diabetes Assistant (HDA) sur le contrôle glycémique suboptimal des patients atteints de diabète de type1.
Combining Glooko and Hedia's technologies could be especially helpful and a “viable alternative” for people who rely on “smart” insulin pens to manually inject multiple insulin doses throughout the day, according to Glooko CEO Russ Johannesson.
Glooko Inc. and Hedia ApS launched an integrated software solution in the U.K. to support people with diabetes who require advanced doses of bolus insulin.

Partnering for progress
At Hedia, we understand that creating sustainable health outcomes requires a holistic approach. That’s why we collaborate with a range of partners in the diabetes ecosystem, including clinics, hospitals, and industry leaders. By working together, we aim to create a better experience for end users and advance diabetes care.